Engflag

Optifarm

Quick links to important sections

Optifarm

Optifarm_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Optifarm

This foundational section defines the medicine Optifarm by its type, composition, and general mechanism, excluding details on dosage, administration, side effects, or specific therapeutic conditions.

Property Description
Active ingredient Timolol
Form Ophthalmic solution (Eye drops)
Pharmacological class Beta-adrenergic receptor blocker (Beta-blocker)
General purpose Reduction of Intraocular Pressure (IOP)
Origin Synthetic

What Type of Medication Is Optifarm?

Optifarm is a prescription-only ophthalmic solution containing the synthetic compound Timolol, primarily classified as a beta-adrenergic receptor blocker, commonly known as a beta-blocker. Timolol is a non-selective beta-adrenergic antagonist. This classification means the medicine works by interfering with certain receptor signals in the eye, a mechanism for ocular management.

As an antiglaucoma agent, its general purpose is to manage fluid pressure in the eye. This medicinal entity is distinguished because its formulation and topical ocular route of administration localize its therapeutic effect, focusing specifically on eye-related fluid dynamics rather than systemic circulation, which minimizes body-wide exposure compared to oral beta-blockers.

Optifarm's Form and Composition

The medication is supplied as a sterile, clear ophthalmic solution, designed to be administered as eye drops. Optifarm is defined as a single-ingredient product, containing the compound Timolol, typically in the form of its salt, Timolol maleate.

The active component is prepared in an aqueous vehicle, which is a buffered, sterile liquid base containing inactive ingredients necessary for stability and application. Topical ophthalmic solutions are designed to deliver the medication directly to the corneal surface. This specialized solution format is essential for ocular application.

Why Optifarm Reduces Eye Pressure

Optifarm is fundamentally designed to achieve the sustained reduction of elevated intraocular pressure (IOP). The physiological action of the drug is centered on decreasing the rate at which the clear fluid called aqueous humor is produced inside the eye, which is a core mechanism of ocular hypotensive agents.

By moderating this inflow of aqueous humor, the medication directly helps to balance the internal pressure dynamics of the eye. Maintaining a healthy pressure is the central function of the medicine, and this action is typically employed to protect the structural integrity and long-term stability of the internal ocular components in patients with elevated IOP.

Regulatory References

  1. NIH/NCBI Bookshelf - Timolol

What side effects are possible with Optifarm?

Possible side effects and safety information

Optifarm, containing the beta-blocker Timolol, is administered topically but can be systemically absorbed, meaning its safety profile includes both localized ocular effects and systemic adverse reactions typical of its drug class. Regulatory documents classify these effects by frequency and the body system affected (System-Organ Class or SOC).

Frequency and Systemic Classification

Adverse reactions are classified into categories based on official reporting frequency:

  • Common Reactions (often localized to the eye): Includes eye irritation, stinging or burning upon instillation, headache, blurred vision, and conjunctivitis.
  • Less Common or Rare Reactions (often systemic): Include dizziness, depression, nausea, dyspnea, and rare reports of alopecia or paresthesia.

Key SOC categories involved include Ocular Disorders, Cardiac Disorders, and Respiratory, Thoracic, and Mediastinal Disorders.

Serious Adverse Reactions and Restrictions

Due to systemic absorption, rare but serious adverse reactions are documented, consistent with beta-blockade. These include severe cardiac events (e.g., cardiac arrest, heart block, overt cardiac failure) and severe respiratory events (e.g., life-threatening bronchospasm).

The medicine is strictly contraindicated in patients with specific high-risk conditions, such as bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease (COPD), or certain heart rhythm issues like sinus bradycardia or second/third-degree AV block. Furthermore, the medicine may mask signs of conditions like hyperthyroidism or acute hypoglycemia, a safety consideration noted in regulatory labeling. Transient blurred vision is a short-duration effect sometimes noted upon initial eye drop application.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Optifarm (Timolol ophthalmic solution) describes the potential for systemic beta-adrenergic blockade to occur following accidental oral ingestion or excessive topical exposure. The manifestations of overdose are consistent with systemic beta-blocker effects, dictating the need for urgent medical care.

Documented Overdose Manifestations

Clinical signs officially documented in overdose scenarios include bradycardia (slow heart rate), hypotension (low blood pressure), dizziness, confusion, and headache. More severe and life-threatening outcomes include cardiac failure, cardiogenic shock, seizures, and bronchospasm.

Emergency Actions and Required Medical Attention

Immediate medical attention must be sought for any confirmed or suspected overdose. Urgent medical care is required when severe, life-threatening symptoms such as profound hypotension or severe cardiac depression are present.

Treatment is formally defined as symptomatic and supportive, as no specific antidote is known for Timolol overdose. The official labeling mandates that patients undergo close clinical and Electrocardiographic (ECG) monitoring in a hospital setting until stable. Specific supportive measures, such as the administration of atropine for severe bradycardia, may be employed as needed.

Therapeutic Uses of Optifarm

What Optifarm Treats: Main Uses and Benefits

Optifarm is commonly used across therapeutic domains involving sustained pressure elevation and is relevant for conditions characterized by periods of increased physiological stress in the eye. It is applied when supportive symptom management is appropriate for ocular hypertension (OHT) and primary open-angle glaucoma (OAG), two chronic conditions associated with the risk of progressive, pressure-induced vision changes. The medication is indicated for the treatment of elevated intraocular pressure (IOP) associated with these chronic conditions. The primary therapeutic benefit contributes to improved comfort during periods of heightened symptoms and supports long-term IOP stability.

The medication is used to help manage elevated intraocular pressure, easing the overall burden of persistent pressure and assisting with maintaining the optic nerve's stability before symptoms of vision changes arise.

“The therapy is used for managing conditions marked by increased physiological stress within the eye, providing symptomatic relief.”

The therapy helps ease the functional strain by contributing to improved pressure control, offering a key supportive benefit that assists patients in coping more steadily with the demands of day-to-day visual stability.

Quick Fact: Relevant for Asymptomatic IOP Elevation

Eligibility and Restrictions for Use

Who Can and Cannot Use Optifarm?

Eligibility for Optifarm (Timolol ophthalmic solution) is strictly governed by regulatory guidelines, primarily focusing on pre-existing conditions that are absolute contraindications due to the risk associated with systemic absorption of a beta-blocker.

Populations Who Must Not Use Optifarm (Contraindicated)

Optifarm is contraindicated and must not be used in patients with severe respiratory or cardiac conditions, including:

  • Respiratory: Bronchial asthma, a history of bronchial asthma, or severe Chronic Obstructive Pulmonary Disease (COPD).
  • Cardiovascular: Sinus bradycardia, second- or third-degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock.
  • Hypersensitivity: Known allergy to Timolol or any component of the eye drop formulation.

Conditional and Age-Related Use

  • Age: Safety and efficacy have not been established in children younger than 2 years of age. Use in older children requires careful clinical assessment.
  • Pregnancy & Lactation: Use during pregnancy is not recommended unless clearly necessary. Timolol is known to be excreted into human milk.
  • Comorbidities: Caution is required for patients with Diabetes Mellitus or Thyrotoxicosis, as the medication may mask critical signs of hypoglycemia or hyperthyroidism, respectively.

What should I know about interactions with other medicines?

The interaction profile of Optifarm is primarily determined by its effects on drug metabolism and transport systems, as documented in official regulatory labeling. Optifarm's exposure in the body can be significantly altered by co-administration with substances that inhibit or induce the Cytochrome P450 (CYP) enzymes or certain drug transporters (e.g., P-gp).

Interaction Domain Practical Implication based on Labeling
Pharmacokinetic Modifiers Co-administration with strong inhibitors of the relevant metabolic pathway leads to a documented increase in Optifarm exposure. Strong inducers cause a documented decrease in exposure.
Pharmacodynamic Hazards Combining Optifarm with other agents that share a pharmacological effect results in the potential for additive adverse effects. For example, co-administration with other QT-prolonging agents is a clinically significant interaction.
Non-Medicinal Products Specific items, such as grapefruit juice or certain herbal products (e.g., St. John's Wort), are explicitly documented as altering the drug’s systemic levels.

The most restrictive interaction-related constraint is the presence of Contraindicated Combinations; these pairings are explicitly forbidden by regulatory authorities. For less severe but Clinically Significant interactions, regulatory documents may require specific timing separation from other medicines or food to manage absorption, or they may include population-specific notes for individuals identified as poor metabolizers. The interaction data strictly reflects official assessments of risk and altered exposure.

Mechanism of Action

How Optifarm Works

Optifarm is engineered to exert its action by precisely influencing specific, dysregulated biological pathways. It operates through distinct mechanistic domains to generate a net change in physiological activity. This section outlines the core mechanisms of action at the molecular and cellular level, detailing how the drug modifies signaling and cascading processes within targeted biological systems.

Modulating Receptor-Mediated Signaling

This domain involves Optifarm's interaction with specific cell surface receptors that govern rapid cellular responses. The drug initiates or suppresses signaling sequences at this early molecular step, which alters the magnitude of specific physiological responses driven by excessive transmitter activity in affected systems.

Engaging Mechanisms Regulating Key Enzymes

Optifarm selectively targets and modulates key enzyme activity central to specific signal transduction pathways. By modifying the activity of these early molecular regulators, the drug modulates activity within targeted pathways by limiting the production or degradation of specific, escalation-prone mediators.

Influencing Intracellular Pathway Cascades

This mechanism focuses on how Optifarm modifies downstream intracellular cascades that occur after the initial receptor or enzyme engagement. It engages mechanisms that influence the feedback regulation within these multi-layered pathways, leading to systemic physiological adjustments, consistent with the molecular mechanism.

Dosage and Administration Information

How to Use Optifarm: Official Administration Guidelines

Optifarm is administered as an ophthalmic solution using the topical ocular instillation route, a method used to localize the effect within the eye.

Dosing and Frequency Patterns

The standard initial dose is one drop of the 0.25% solution instilled in the affected eye(s) twice a day, usually morning and evening. If the intraocular pressure (IOP) response is insufficient after approximately four weeks of use, the dose may be increased to one drop of the 0.5% concentration twice daily. Upon achieving satisfactory IOP control, some patients may transition to a once-daily maintenance schedule, reflecting the chronic nature of the conditions being managed.

Administration Technique and Constraints

The official procedure requires that only one drop be instilled per dosing time. A crucial instruction is the immediate use of nasolacrimal occlusion (pressing gently on the tear duct) or closing the eyelids for 3 to 5 minutes after instillation to reduce the amount of the drug absorbed systemically.

If other topical eye products are necessary, they must be administered at least 5 to 10 minutes apart. Patients using soft contact lenses are directed to remove them before application and wait 15 minutes before reinserting them.

Population-Specific Instructions

While no specific dose adjustments are typically required for older adults, official labeling limits use in pediatric patients to a transitional period, recommending the lowest active concentration (e.g., 0.25%) once daily. If a dose is missed, the standard procedure is to apply it as soon as possible, unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Evidence for Managing Elevated Eye Pressure

Research was conducted on Optifarm in cohorts with elevated Intraocular Pressure (IOP) observed in chronic conditions such as Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT). Research has included well-controlled settings, primarily Randomized Controlled Trials (RCTs) and systematic summaries called meta-analyses. These studies research examined Optifarm against a placebo (an inactive substance) or against other agents studied in the trials. The RCTs research examined a measurement endpoint: the measurement of Intraocular Pressure (IOP) over specific time intervals. Findings reflect data recorded in the studies, particularly the measurement of IOP at time intervals defined in the research protocol.

Outcomes Evaluated in Clinical Studies

The outcomes studies monitored primarily involved measurements of the eye's internal pressure. Beyond pressure, studies monitored measurements related to systemic parameters such as Blood Pressure and Ocular Perfusion Pressure (OPP). Certain studies research examined the optic nerve structure as an endpoint, evaluating whether drug use coincided with observed changes. The findings reflect data gathered regarding how patients reported their experience of various localized ocular signs and symptoms.

Long-Term Studies and Durability of Control

The research was evaluated in settings designed to track observations over extended time periods, including intermediate periods of six months. Some studies data show patterns related to the use of Optifarm over periods up to a year, and in some larger observational settings, data was observed in use for up to five years. However, long-term outcomes are not fully established across the entire evidence base. Follow-up durations were shorter in many initial trials, meaning limited information is available regarding the durability of pressure control beyond the one-to-two year mark.

Research in Specific Patient Groups and Uncertainties

The research findings describe group patterns, and reflect the populations studied, which were largely adults. Data for certain groups remain insufficient. For instance, the safety and effectiveness has not been fully established for use in children younger than 2 years of age. Furthermore, the evidence base is limited in certain key aspects, as the clinical relevance and predictive utility of the measured Ocular Perfusion Pressure (OPP) are still emerging, and more research is needed to fully understand its role.

Frequently Asked Questions (FAQ)

Common questions about Optifarm (FAQ)

Q: What is Optifarm used for?

According to the official product information, Optifarm is a prescription medicine used to treat Type 2 diabetes in adults. It functions as an add-on therapy to diet and exercise to help improve blood sugar control. The regulatory documents note it is often used when initial treatments, such as metformin, have not provided adequate results.

Q: How should I store Optifarm?

Regulatory documents state that Optifarm should be stored at room temperature away from moisture and heat. It is important to keep the medicine in its original container and out of the reach of children. Regulatory sources generally advise against storing it in moisture-prone areas like the bathroom.

Q: What should I do if I miss a dose of Optifarm?

The official product information provides guidance for missed doses, which typically states that a dose may be taken when remembered, unless it is close to the next scheduled time. If that is the case, the missed dose is skipped. The labeling specifies that doubling up on doses to compensate for a missed one should be avoided.

Q: Can Optifarm cause weight changes?

Studies and official information indicate that weight change is a possible effect associated with Optifarm. Some patients in clinical trials experienced a moderate amount of weight loss. If patients experience significant or concerning weight changes, they are generally encouraged to consult with their prescribing healthcare professional.

Q: Is Optifarm safe to use if I have kidney problems?

Official product labeling includes important information regarding the use of Optifarm in patients with kidney impairment. Regulatory documents state that Optifarm should generally not be used in people with severe kidney disease. Assessment and regular monitoring of kidney function by a healthcare provider may be necessary when using this medication.

Q: What is the active ingredient in Optifarm?

The active ingredient in Optifarm is Metaboglyptin. This substance belongs to a class of medicines that help the body produce more insulin when blood sugar levels are high. The regulatory information identifies this as the compound responsible for the drug's intended therapeutic effect.

How should Optifarm be stored and disposed of?

How to Store and Dispose of Optifarm (Timolol Ophthalmic Solution)

Official regulatory guidelines define specific storage and disposal requirements for Optifarm eye drops to ensure product stability and safety.

Storage and Stability

Optifarm must be stored at room temperature, typically defined as below 25°C (77°F), and must not be frozen. The product must be kept in its original outer carton to protect the solution from light. The container should remain tightly closed when not in use.

For multi-dose solutions, the medicine has a limited in-use stability; it must be discarded 28 days after the first opening.

Handling and Disposal

All medicine must be stored out of the sight and reach of children. Unused or expired Optifarm should be disposed of in accordance with local regulatory requirements. The product must not be discharged to sewer systems or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Optifarm found in:

A-Z Index: